Zinc acetate - Teva Pharmaceuticals

Drug Profile

Zinc acetate - Teva Pharmaceuticals

Alternative Names: Galzin; Wilzin; Zinc acetate dihydrate - Teva Pharmaceuticals

Latest Information Update: 13 Aug 2015

Price : $50

At a glance

  • Originator Lemmon
  • Developer Orphan Europe; Teva Pharmaceuticals USA
  • Class Acetates; Antiacnes; Antidiarrhoeals; Heavy metals
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatolenticular degeneration
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatolenticular degeneration

Most Recent Events

  • 13 Aug 2015 Launched for Wilson's disease in Slovenia, Lithuania, Slovakia and Latvia (PO) before August 2015
  • 30 Apr 2015 Launched for Wilson's disease in Greece (PO) before April 2015
  • 03 Feb 2015 Launched for Wilson's disease in Austria (PO) before February 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top